Form 8-K - Current report:
SEC Accession No. 0001193125-24-000219
Filing Date
2024-01-02
Accepted
2024-01-02 07:30:59
Documents
12
Period of Report
2023-12-28
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d680834d8k.htm   iXBRL 8-K 26955
  Complete submission text file 0001193125-24-000219.txt   145883

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ngm-20231228.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20231228_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20231228_pre.xml EX-101.PRE 10809
6 EXTRACTED XBRL INSTANCE DOCUMENT d680834d8k_htm.xml XML 3296
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 24500220
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)